Specialized Genasense(R) Clinical Trials Featured At AACR Meeting
Genta Incorporated (Nasdaq: GNTA) announced that presentations related to Genasense(R) (oblimersen sodium) Injection, the Company’s lead anticancer compound will be featured at the annual meeting of the American Association for Cancer Research (AACR). The meeting will be held in San Diego, CA from April 12-16, 2008.
Original post by Allergy News From Medical News Today
Related Articles
Foremost International Meeting Highlights Breakthroughs In Cancer Research
Oncology Drug Development Update-Targeted Drugs From The 2007 Meeting Of The American Association Of Cancer Research (AACR)
Genasense(R) Clinical Data In Patients With Advanced Melanoma And Chronic Lymphocytic Leukemia To Be Presented At ECCO Meeting In Barcelona
Molecular Diagnostics In Cancer Therapeutic Development Meeting Hosted By AACR
New Data From Several Satraplatin Clinical Trials In Solid Tumors Presented At 44th ASCO Annual Meeting
Foremost International Meeting Highlights Breakthroughs In Cancer Research
Oncology Drug Development Update-Targeted Drugs From The 2007 Meeting Of The American Association Of Cancer Research (AACR)
Genasense(R) Clinical Data In Patients With Advanced Melanoma And Chronic Lymphocytic Leukemia To Be Presented At ECCO Meeting In Barcelona
Molecular Diagnostics In Cancer Therapeutic Development Meeting Hosted By AACR
New Data From Several Satraplatin Clinical Trials In Solid Tumors Presented At 44th ASCO Annual Meeting